Delaware Clinical and Translational Research ACCEL Program

特拉华州临床和转化研究 ACCEL 计划

基本信息

批准号：
10885455
负责人：
Gregory E Hicks
金额：
$ 20.91万
依托单位：
UNIVERSITY OF DELAWARE
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-25 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10885455
关键词：
Acceleration Adult African American Agreement American Area Asian Award Biometry Black race Budgets Caucasians Cessation of life Child Health Childhood Clinical Clinical Research Communities Community Outreach Delaware Development Epidemiology Equity Ethnic Origin Evaluation Funding Goals Grant Growth Health Health Promotion Healthcare Healthcare Systems Hispanic Hospitals Infrastructure Institution Intention Investments Learning Letters Malignant Neoplasms Mission Modeling Modification Native Americans Obesity Outreach Research Pharmaceutical Preparations Pilot Projects Population Population Heterogeneity Population Research Recommendation Research Design Research Personnel Rural Scientist Societies Structure System Time Training Translational Research Universities Work Writing clinical infrastructure community engagement design health care quality health equity health inequalities hospitalization rates improved innovation member multiple chronic conditions population health programs racial diversity recruit translational research program translational scientist

项目摘要

ABSTRACT- OVERALL This proposal is a competitive renewal of the Institutional Development Award Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54) grant originally awarded in September 2013 to the University of Delaware. The ACCEL CTR Program, has completed nine years of funding at the time of this application. During our third funding cycle (ACCEL3), our consortium will consist of four partners: University of Delaware (UD)—the lead institution; Nemours Children’s Health (Nemours); Christiana Care Health System (CCHS), the largest health care system in Delaware; and Delaware State University (DSU), an American historically Black, public university that joined our consortium during the last competitive renewal. Over the past nine years, ACCEL has established an exceedingly strong network and infrastructure for clinical and translational (C&T) research within the state of Delaware; and, we are now poised and ready to continue our growth trajectory. While we will continue with the activities that have made us successful, we will have a sharper focus on building sustainable infrastructure across the state that can continue to thrive and mature for years to come. And, we will focus on creating a scientific culture focused, not only, on improving the health of Delawareans, but doing so through a lens of health equity. In our mission to establish a cadre of successful C&T scientists in DE, we will use various approaches to promote full consideration of how their work impacts the needs of all members of society, from design to study implementation to dissemination of findings. And, we will have a much greater focus on building a bi-directional relationship between our scientists and the community so that we can have a greater impact on Delawareans. Delaware is an ideal state for a CTR grant as it represents the whole of the USA in a compact form. The population of Delaware (~970,000) mirrors the US population in urban-to-rural citizen ratio and ethnic/racial diversity, with 23% African American, 62% Caucasian, 10% Hispanic, 4% Asian and 1% Native American. Thus, studies involving a cross-section of Delaware can be generalizable to populations nationally. The dominance of adult (CCHS) and pediatric (Nemours) hospital systems, which serve at least 85% of the residents of the state, provides a unique opportunity to treat the state of Delaware as a model for examining how healthcare changes can impact population health. The overarching goal of the ACCEL CTR Program is to create a unified Delaware Clinical and Translational Research Community (inclusive of investigators and community members) that breaks down existing barriers, capitalizes on the unique strengths of its partners to establish infrastructure and accelerates the creation of equitable solutions that improve the health of all Delawareans and all Americans.

摘要 - 总体该提案是对机构发展奖计划基础设施的竞争续约临床和转化研究（IDEA-CTR）（U54）赠款最初于2013年9月授予特拉华大学。加速CTR计划已完成了9年的资金此应用程序。在我们的第三个资金周期（ACCEL3）中，我们的财团将由四个合作伙伴组成：特拉华大学（UD） - 领导机构； Nemours儿童健康（Nemours）；克里斯蒂安娜特拉华州最大的医疗保健系统护理卫生系统（CCHS）；和特拉华州立大学（DSU），一所美国历史上的黑人公立大学，在上次加入我们的财团竞争性更新。在过去的九年中，Accel建立了一个非常强大的网络以及特拉华州临床和转化（C＆T）研究的基础设施；而且，我们是现在中毒并准备继续我们的成长轨迹。虽然我们将继续进行活动使我们取得了成功，我们将更加专注于建立可持续基础设施未来几年可以继续蓬勃发展和成熟的国家。而且，我们将专注于创建科学文化不仅以改善特拉华州的健康为重点，而且通过镜头进行健康公平。为了在DE建立成功的C＆T科学家的干部，我们将使用各种方法以促进其工作如何影响所有成员的需求的各种方法社会，从设计到研究实施再到发现结果。而且，我们将有很多更加专注于在我们的科学家与社区之间建立双向关系，以便我们可以对德拉瓦人产生更大的影响。特拉华州是CTR赠款的理想状态以紧凑的形式代表整个美国。特拉华州（〜970,000）的人口反映了美国城市与农村公民比例和种族/种族多样性的人口，有23％的非裔美国人，62％高加索人，10％的西班牙裔，4％的亚洲人和1％的美国原住民。这是研究涉及的特拉华州可以在全国范围内推广到人口。成人（CCHS）和小儿的优势（Nemours）医院系统至少为该州的居民提供至少85％的医院系统，提供了独特的将特拉华州作为研究医疗保健变化如何影响的模型的机会人口健康。加速CTR计划的总体目标是创建一个统一的特拉华临床和转化研究社区（包括研究人员和社区成员）打破现有的障碍，利用其合作伙伴的独特优势建立基础设施并加速建立公平解决方案，以改善所有人的健康状况德拉瓦人和所有美国人。

项目成果

期刊论文数量（287）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Comprehensive pain management strategy for infants with moderate to severe osteogenesis imperfecta in the perinatal period.

DOI：
10.1002/pne2.12066
发表时间：
2021-12
期刊：
Paediatric & neonatal pain
影响因子：
0
作者：
Carroll RS;Donenfeld P;McGreal C;Franzone JM;Kruse RW;Preedy C;Costa J;Dirnberger DR;Bober MB
通讯作者：
Bober MB

Disparities in Delaware Caregiver Beliefs about the COVID-19 Vaccine for their Children.